삼성서울병원

Ko En

Hematology-Oncology LIM, SUNG HEE M.D , Ph.D

Expertise
Gastric cancer, Colorectal cancer, Genitourinary cancer
Treament Schedule 05 月
DATE
THU
01
FRI
02
SAT
03
SUN
04
MON
05
TUE
06
WEB
07
THU
08
FRI
09
SAT
10
SUN
11
MON
12
TUE
13
WEB
14
THU
15
FRI
16
SAT
17
SUN
18
MON
19
TUE
20
WEB
21
THU
22
FRI
23
SAT
24
SUN
25
MON
26
TUE
27
WEB
28
THU
29
FRI
30
SAT
31
AM
PM
Treament Schedule 06 月
DATE
SUN
01
MON
02
TUE
03
WEB
04
THU
05
FRI
06
SAT
07
SUN
08
MON
09
TUE
10
WEB
11
THU
12
FRI
13
SAT
14
SUN
15
MON
16
TUE
17
WEB
18
THU
19
FRI
20
SAT
21
SUN
22
MON
23
TUE
24
WEB
25
THU
26
FRI
27
SAT
28
SUN
29
MON
30
AM
PM

Medical Education

2014~2020 Ph.D. in Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea
2013~2015 Master of Science, Sungkyunkwan University School of Medicine, Seoul, Korea
2003~2009 College of Medicine, Yonsei University, Seoul, Korea

Post-Graduate Training

Fellowship   2014~2016 Fellowship, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Residency   2010~2014 Residency, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Internship   2009~2010 Internship, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Professional Appointments

2024~Present Associate Professor, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Kore
2023~2024 Assistant Professor, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2017~2023 Assistant Professor, Division of Oncology-Hematology Department of Internal medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
2016~2017 Clinical Fellowship, Division of Hematology-Oncology, Department of Medicine, Dongtan Sacred Heart Hospital, Hallym University of College of Medicine, Hwaseong, Korea

Professional Memberships

2014~Present Member, ASCO American Society of Clinical Oncology
2014~Present Member, ESMO European Soceity of Medical Oncology
2014~Present Member, KSMO Korean Soceity of Medical Oncology
2014~Present Member, KCSG Korean Cancer Study Group

Selected Publications

  • ONCOL RES 2025 10.32604/or.2024.049054 Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab Kim, R; Park, JK; Kwon, M; An, M; Hong, JY; Park, JO; Lim, SH; Kim, ST
    View PubMed
  • FRONT ONCOL 2024 10.3389/fonc.2024.1450732 TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice Shin, JE; Lim, SH; Lee, J; Lim, HY; Park, YS; Kim, ST
    View PubMed
  • CANCERS 2024 10.3390/cancers16172969 The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer Lim, SH; Kim, MJ; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • PATHOL RES PRACT 2024 10.1016/j.prp.2024.155473 Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis Choi, DH; Jang, HL; Lim, SH; Kim, ST; Hong, JY; Park, SH; Park, JO; Kim, DG; Kim, KM; Lee, J
    View PubMed
  • WORLD J GASTRO ONCOL 2024 10.4251/wjgo.v16.i8.3521 Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1 Kang, SW; Lim, SH; Kim, MJ; Lee, J; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.1226 Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study Lee, J; Lim, SH; Chung, JH; Song, W; Sung, HH; Jeong, BC; Park, SH
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2024.015 Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies Cho, SW; Lim, SH; Kwon, GY; Kim, CK; Park, W; Pyo, H; Chung, JH; Song, W; Sung, HH; Jeong, BC; Park, SH
    View PubMed
  • TRANSL CANCER RES 2024 10.21037/tcr-24-20 CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells Lim, SH; Lee, SY; Hong, JY; Lee, J; Kim, ST
    View PubMed
  • CANCER LETT 2024 10.1016/j.canlet.2024.217041 The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial Lim, SH; Saluja, A; Vickers, S; Hong, JY; Kim, ST; Lavania, S; Pandey, S; Gupta, VK; Velagapudi, MR; Lee, J
    View PubMed
  • BIOMATERIALS 2024 10.1016/j.biomaterials.2024.122504 Patient-derived tumor spheroid-induced angiogenesis preclinical platform for exploring therapeutic vulnerabilities in cancer Ko, JH; Hyung, S; Heo, YJ; Jung, SM; Kim, ST; Park, SH; Hong, JY; Lim, SH; Kim, KM; Yoo, S; Li Jeon, N; Lee, JY
    View PubMed
  • BMC CANCER 2024 10.1186/s12885-024-11972-w Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06) Lim, SH; Lee, KW; Kim, JJ; Im, HS; Kim, IH; Han, HS; Koo, DH; Cho, JH; Maeng, CH; Lee, MY; Lee, HJ; Kim, JH; Park, SG; Jung, JY; Shin, SH; Kim, KH; Kim, H; Oh, SY; Kang, MS; Jung, MKY; Rha, SY
    View PubMed
  • BIOMEDICINES 2023 10.3390/biomedicines11123264 Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data Lim, SH; Jung, J; Hong, JY; Kim, ST; Park, SH; Park, JO; Kim, KM; Lee, J
    View PubMed
  • J GASTROINTEST ONCOL 2023 10.21037/jgo-23-598 The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer Jeon, Y; Lim, SH; Lee, J; Kang, WK; Jang, JY; Jeong, SY; Choi, D; Kim, ST
    View PubMed
  • ONCOL RES 2023 10.32604/or.2023.030374 Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer Lim, SH; Cho, HJ; Kim, KM; Lim, HY; Kang, WK; Lee, J; Park, YS; Kim, HC; Kim, ST
    View PubMed
  • ANTICANCER RES 2023 10.21873/anticanres.16607 Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study Lim, SH; Hong, JY; Park, JO; Park, YS; Kim, ST
    View PubMed
  • J GASTROINTEST ONCOL 2023 10.21037/jgo-23-375 Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes Jang, JY; Jeon, YK; Jeong, SY; Lim, SH; Park, YS; Lim, HY; Lee, JY; Kim, ST
    View PubMed